Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Vulcan Value Partners LLC

Vulcan Value Partners LLC increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 119.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 101,338 shares of the company’s stock after acquiring an additional 55,237 shares during the quarter. Vulcan Value Partners LLC owned approximately 0.33% of Medpace worth $33,668,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. R Squared Ltd acquired a new position in Medpace in the 4th quarter valued at about $30,000. SBI Securities Co. Ltd. acquired a new position in Medpace in the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp lifted its holdings in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC grew its position in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the period. Finally, Assetmark Inc. increased its stake in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

MEDP opened at $298.55 on Friday. The business has a fifty day moving average price of $313.79 and a 200 day moving average price of $331.76. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $459.77. The stock has a market capitalization of $9.02 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same period in the prior year, the firm earned $3.20 earnings per share. On average, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on MEDP. Truist Financial cut their price objective on Medpace from $333.00 to $300.00 and set a “hold” rating for the company in a research report on Wednesday. Robert W. Baird dropped their price target on shares of Medpace from $340.00 to $313.00 and set a “neutral” rating for the company in a research report on Wednesday. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a report on Monday, March 24th. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price for the company. Finally, TD Cowen cut Medpace from a “buy” rating to a “hold” rating and decreased their price target for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.